A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia
(MDS) are limited. Although stem cell transplantation remains one of the most effective
treatments it is associated with severe side effects which have until recently prevented its
use in older adults. In the last decade the use of reduced intensity transplants has allowed
the extension of the potentially curative effect of transplantation to older patients in whom
it was previously precluded. Although a major advance such transplants are associated with a
high risk of disease relapse particularly in patients with high risk disease.
This study will evaluate new transplant strategies with the aim of improving the outcome of
patients with AML and high risk MDS after stem cell transplantation. Three approaches to
improve transplant outcome will be studied:
1. Comparing the new pre-transplant consolidation therapy vyxeos with the standard
consolidation therapy
2. Comparing new conditioning therapies in patients under the age of 55 years
3. Comparing new conditioning therapies in patients aged 55 and over
All patients will be followed up for a minimum of 2 years.